J9355 Injection trastuzumab excl biosimi
Also known as: trastuzumab, Herceptin
Injection of trastuzumab excluding biosimilars, an anti-HER2 monoclonal antibody. First-line therapy for HER2-positive breast cancer.
In Plain Language
breast cancer injection; HER2 targeted therapy
Clinical Context
Standard therapy for HER2-positive breast cancer in early and metastatic settings. Often combined with chemotherapy and other targeted agents.
RVU Information
CPT J9355 does not have a physician work RVU assigned by CMS. This is typical for supply, drug, and equipment codes — reimbursement is based on Average Sales Price (ASP), fee schedules, or payer contracts rather than the RVU system.
Billing & Documentation
J-codes represent drugs administered by a healthcare provider (not self-administered). Documentation must include the drug name, dosage, route of administration, and medical necessity. Most payers require the National Drug Code (NDC) on the claim. Bill the appropriate administration code (96365-96379) in addition to the drug code.
Specialties
Frequently Asked Questions
What is CPT code J9355?
CPT J9355 (Injection trastuzumab excl biosimi) is a J Codes (Drugs) code. Injection of trastuzumab excluding biosimilars, an anti-HER2 monoclonal antibody. First-line therapy for HER2-positive breast cancer.
How is J9355 administered?
CPT J9355 is administered by a healthcare provider, typically via injection or infusion. Standard therapy for HER2-positive breast cancer in early and metastatic settings. Often combined with chemotherapy and other targeted agents. It is used by Oncology, Surgery, Internal Medicine.
When is CPT J9355 used?
Standard therapy for HER2-positive breast cancer in early and metastatic settings. Often combined with chemotherapy and other targeted agents.
Track This Code in RVU Edge
Log procedures, calculate wRVUs, and benchmark against MGMA data — all in one app.
CPT® is a registered trademark of the American Medical Association. Data sourced from CMS Physician Fee Schedule RVU26A. Descriptions, synonyms, and clinical context are original content by RVU Edge.